← Back to guidelines
Cardiology12 papers

Glanzmann's thrombasthenia

Last edited: 4/15/2026

Overview

Glanzmann's thrombasthenia (GT) is a rare inherited bleeding disorder characterized by impaired platelet aggregation due to defects in the GPIIb/IIIa integrin complex, leading to severe bleeding tendencies 12.

Diagnosis

  • Deficiency or dysfunction of GPIIb/IIIa (αIIbβ3) integrin confirmed by flow cytometry or platelet aggregation studies 12.
  • Bleeding time significantly prolonged 1.
  • Platelet aggregation typically absent or markedly reduced with standard agonists like ADP, collagen, and thrombin 12.
  • Management

  • First-line treatment: Platelet transfusions to manage acute bleeding episodes 1.
  • Adjunctive treatments:
  • - Recombinant activated factor VII (rFVIIa) at 90 μg/kg per infusion for managing bleeding episodes, especially in refractory cases or those with anti-GPIIb/IIIa antibodies 1. - Antifibrinolytic agents (e.g., tranexamic acid) may be used in conjunction with rFVIIa 1.

    Special Populations

  • Pediatrics: Dental extractions can often be performed successfully without supplemental therapy in children, though close monitoring is essential 3.
  • Pregnancy: Specific management strategies not detailed in provided abstracts; individualized care with close surveillance recommended 1.
  • Key Recommendations

  • Use recombinant activated factor VII (rFVIIa) at 90 μg/kg per infusion for managing bleeding episodes in Glanzmann's thrombasthenia, particularly in cases with anti-GPIIb/IIIa antibodies or transfusion refractoriness (Evidence: Moderate) 1.
  • Platelet transfusions remain the standard for acute bleeding control, though monitor for development of alloantibodies (Evidence: Expert opinion) 1.
  • Consider antifibrinolytic agents as adjunctive therapy during surgical interventions to reduce bleeding risk (Evidence: Weak) 1.
  • References

    1 Saultier P, Grino M, Falaise C, Voisin S, Lavenu-Bombled C, Ibrahim-Kosta M et al.. Efficacy and safety of recombinant activated factor VII in Glanzmann thrombasthenia: A systematic literature review. Haemophilia : the official journal of the World Federation of Hemophilia 2025. link 2 Coller BS, Shattil SJ. The GPIIb/IIIa (integrin alphaIIbbeta3) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bend. Blood 2008. link 3 Jasmin JR, Dupont D, Velin P. Multiple dental extractions in a child with Glanzmann's thrombasthenia: report of case. ASDC journal of dentistry for children 1987. link

    Original source

    1. [1]
      Efficacy and safety of recombinant activated factor VII in Glanzmann thrombasthenia: A systematic literature review.Saultier P, Grino M, Falaise C, Voisin S, Lavenu-Bombled C, Ibrahim-Kosta M et al. Haemophilia : the official journal of the World Federation of Hemophilia (2025)
    2. [2]
    3. [3]
      Multiple dental extractions in a child with Glanzmann's thrombasthenia: report of case.Jasmin JR, Dupont D, Velin P ASDC journal of dentistry for children (1987)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG